Associations between brain inflammatory profiles and human neuropathology are altered based on apolipoprotein E ε4 genotype

Jacob S. Friedberg1, Nurgul Ayta1n1,2,3, Jonathan D. Cherry1,2,3, Weiming Xia4, Oliver J. Standring1,3, Victor E. Alvarez1,2,3,4, Raymond Nicks1, Sarah Svirsky1,3,4, Gaoyuan Meng3,4, Gyungah Jun6,7,9, Hoon Ryu2,3, Rhoda Au1,2,8,9 & Thor D. Stein1,3,4,5,8*

Alzheimer disease (AD) is a chronic neurodegenerative disease with a multitude of contributing genetic factors, many of which are related to inflammation. The apolipoprotein E (APOE) ε4 allele is the most common genetic risk factor for AD and is related to a pro-inflammatory state. To test the hypothesis that microglia and AD-implicated cytokines were differentially associated with AD pathology based on the presence of APOE ε4, we examined the dorsolateral frontal cortex from deceased participants within a community-based aging cohort (n = 154). Cellular density of Iba1, a marker of microglia, was positively associated with tau pathology only in APOE ε4 positive participants (p = 0.001). The cytokines IL-10, IL-13, IL-4, and IL-1α were negatively associated with tau pathology, independent of Aβ1–42 levels, only in APOE ε4 negative participants. Overall, the association of mostly anti-inflammatory cytokines with less tau pathology suggests a protective effect in APOE ε4 negative participants. These associations are largely absent in the presence of APOE ε4 where tau pathology was significantly associated with increased microglial cell density. Taken together, these results suggest that APOE ε4 mediates an altered inflammatory response and increased tau pathology independent of Aβ1–42 pathology.

Alzheimer’s disease (AD), the leading cause of dementia, is a progressive neurodegenerative disorder with both genetic and environmental risk factors. Many of the genes associated with AD have small effects and are associated with immunological and inflammatory pathways in the brain1,2. In contrast, the apolipoprotein E (APOE) ε4 allele is associated with a dramatic increase in the risk of developing AD and a younger age of symptom onset3,4. APOE may contribute to the development of AD through a variety of mechanisms, including increased beta-amyloid (Aβ) levels as well as an altered neuroinflammatory state.

Studies examining human post-mortem brain tissue found an increased number of microglia within AD patients with APOE ε45,6. Minett et al.7 found that increased microglia levels were negatively associated with AD pathology in non-demented individuals while the opposite was observed in demented individuals. Furthermore, APOE ε4 was associated with increased microglial activation and worse tau pathology and clinical outcomes7. In addition, peripheral low-grade inflammation was associated with risk of AD in APOE ε4, but not ε2 or ε3 carriers8. These studies suggest the APOE ε4 allele may lead to AD pathology through an altered inflammatory state. However, the precise role of APOE ε4 in modulating the relationship between microglia and inflammatory cytokines with the development of AD pathologies in the human brain is largely unknown.

1Boston University Alzheimer’s Disease and CTE Center, Boston University School of Medicine, Boston, MA, 02118, USA. 2Department of Neurology, Boston University School of Medicine, Boston, MA, 02118, USA. 3VA Boston Healthcare System, Boston, MA, 02130, USA. 4Department of Veterans Affairs Medical Center, Bedford, MA, 01730, USA. 5Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA, 02118, USA. 6Department of Biostatistics, Boston University School of Medicine, Boston, MA, 02118, USA. 7Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA. *email: tdstein@bu.edu
Multiple cytokines have been implicated in AD pathogenesis. These include both the generally pro-inflammatory cytokines IL-1α and β, TNF-α, and IFN-γ as well as the anti-inflammatory IL-4, IL-10, and IL-13. Pro-inflammatory cytokines may initially reduce pathology by clearing amyloid and tau but may become toxic over time. Anti-inflammatory cytokines have been associated with decreased levels of pro-inflammatory cytokines and increased neurogenesis in mouse models of AD12–14. A recent study by Taipa et al. found that a collection of both pro-inflammatory and anti-inflammatory cytokines were correlated with increased cognition and less cognitive decline in AD patients after one year, suggesting that a balance of cytokines is important for maintaining a less pathologic immune profile15. The effective loss of this balance and increased inflammation may contribute to the progression of AD pathology13,14. Overall, cytokines released from microglia may help determine the prevailing inflammatory state within the brain15. However, opposing results have been reported on the impact of cytokines on AD pathology and symptoms based primarily on mouse models and human blood and CSF15–20. Few studies have examined these relationships in human brain tissue and in relationship to APOE ε4 status. Thus, we aim to elucidate the effect of pro-inflammatory and anti-inflammatory cytokines on AD pathology within frontal cortical tissue in relationship to APOE genotype. Overall, the role of microglia in attenuating or facilitating the development of AD pathologies may be mediated by the specific factors they release and the balance between pro-inflammatory and anti-inflammatory cytokines.

Here we examine the dorsolateral frontal cortex, a region where Aβ develops early and tau pathology develops late, in a community-based aging cohort in order to study the age dependent relationships between known inflammatory cytokines and AD pathologies. We sought to test the hypothesis that the presence of the APOE ε4 allele alters the interaction between microglia and associated cytokines with AD pathology.

Methods

In the present study, we examined 154 autopsy participants from the Framingham Heart Study (FHS). The FHS is a community-based cohort that longitudinally tracks participants and their offspring using previously published selection criteria and protocols. Participants who agreed to brain donation were enrolled and tissue was collected after death with informed consent from the next of kin. Methods were carried out in accordance with and approved by the institutional review boards from both the Boston University Medical Center and the Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA.

Pathological assessment. Neuropathological assessment was performed following procedures and criteria previously established by the Department of Veterans Affairs-Boston University brain bank21,22. Alzheimer disease was diagnosed based on the National Institute of Aging Reagan criteria. Alzheimer disease staging was performed according to the Braak and Braak staging for neurofibrillary tangles23 and the Consortium to Establish a Registry for Alzheimer Disease (CERAD) semi-quantitative criteria for neuritic plaques25. Neuritic plaques were defined as plaques with argyrophilic dystrophic neurites, with or without dense amyloid cores26.

Immunohistochemistry. Tissue was fixed in periodate-lysine-paraformaldehyde, tissue blocks were paraffin-embedded, and sections were cut at 10 μm for immunohistochemistry. Antigen retrieval for α-synuclein and β-amyloid was performed with formic acid treatment for two minutes. Sections were incubated overnight at 4°C with antibodies to phosphorylated PHF-tau (AT8; Pierce Endogen, Rockford IL; 1:2000), ionized calcium binding adaptor molecule 1 (Iba1) (Wako, 1:500), and CD68 (Vector, 1:500). Sections were washed three times with PBS for 15 minutes, after which the supernatant was applied to the immunoassays.

Microscopic analysis of Tau and Microglia density. Tissue blocks from the dorsolateral frontal cortex were embedded in paraffin and cut at 10 μm (AT8) or 20 μm (Iba1 and CD68). Slides immunostained for...
tau (AT8), microglia overall (Iba1), and activated microglia (CD68) were scanned at 20× magnification with a Leica Aperio Scanscope (Leica Biosystems, Buffalo Grove, IL) as previously described\(^27\). Briefly, using ImageScope (Leica Biosystems, Buffalo Grove, IL), the gray matter was highlighted from the pia to the boundary of the white and gray matters. Leica's image analysis and automated counting software (Aperio nuclear algorithm, Version 9) was calibrated for shape, size, and staining intensity to detect AT8-positive NFTs, Iba1-positive cells, and CD68-positive cells within the region of interest. Counts were normalized to the area measured and are presented as density within the analyzed region.

**APOE genotyping.** APOE genotype was determined from DNA extracted from participant brain tissue using single nucleotide polymorphism (National Center for Biotechnology Information SNPs rs429358 and rs7412) as previously described\(^28\). Participants were divided into APOE positive, which included genotypes ε2/ε4 (n = 2), ε3/ε4 (n = 30), and ε4/ε4 (n = 3), and APOE negative, including ε2/ε2 (n = 1), ε2/ε3 (n = 10), and ε3/ε3 (n = 98).

**Statistical analysis.** Statistical analysis was performed with SPSS version 25.0 (IBM inc., Armonk, NY) and Prism v8 (Graphpad Software, La Jolla, CA). IHC cellular density data – AT8, Iba1, CD68 – was analyzed as positive pixel count per mm\(^2\).

A total of 154 cases with complete data were included in the study. Levels of AT8, IL-10, IL-13, IL-4, IL-1β, IL-1α, and IFN-γ were normalized by logarithmic correction. Aβ measures were not normally distributed after log or square root corrections and therefore divided into quartiles and used as an ordinal variable. The raw data for Iba1, CD68, and TNF-α were normally distributed and needed no correction. Outliers were defined by values 3 times the interquartile range away from the upper and lower limits of the interquartile range for each measure and cases were removed from the dataset. In order to allow comparison, participants were divided into groups with and without an APOE ε4 allele.

To assess the variance between APOE ε4 carrier and non-carrier groups with respect to demographic and neuropathological characteristics we applied a chi-square test for proportions and independent samples T-tests. We used separate ordinal logistic regression models to estimate the relative odds of a one quartile increase in Aβ levels for a unit increase in microglial cell densities as well as cytokine levels adjusting for age and sex. Multiple linear regressions were used to test associations between microglial cell densities and tau pathology density and between cytokines and tau pathology adjusting for age, sex, and Aβ\(_{1–42}\). Analyses for each cytokine were run separately to avoid collinearity issues. Multiple comparisons were accounted for using Bonferroni correction. Binary logistic regressions were used to assess the relationship of drivers with dementia.

**Results**

Of the 154 participants from the FHS cohort analyzed there were 119 APOE ε4 negative and 35 were APOE ε4 positive. These two groups varied significantly by frequency of AD, cerebral amyloid angiopathy (CAA), and dementia such that the APOE ε4 carriers group had a higher prevalence. The mean level of tau pathology (AT8 density) was higher in APOE ε4 positive participants than APOE ε4 negative (Table 1). IL-13 and IL-4 had higher levels on average in APOE ε4 negative than APOE ε4 positive participants (Table 2). To test whether there was an effect of an interaction between APOE ε4 genotype and sex on tau pathology, a two-step linear regression adjusting for sex, APOE ε4, and sex-APOE ε4 interaction term was performed. The presence of APOE ε4 was significantly related to tau pathology (p = 0.007) independent of sex but the interaction term was not (p = 0.947). This suggests that the effect of APOE ε4 on tau pathology is independent of sex.

**Associations between microglia and AD pathological markers.** To test the hypothesis that the presence of the APOE ε4 allele altered the relationship between microglia and amyloid and tau pathology we examined these associations separately in participants with and without the APOE ε4 allele. Scatter plots of APOE ε4 positive and negative groups demonstrate significantly different associations between microglia cell density and AD pathology such that Iba1 was positively associated with the log of AT8 in APOE ε4 positive participants, but displayed no significant association in APOE ε4 negative participants (Fig. 1). In order to adjust for the effects of other potential drivers of pathology, we performed multiple regression analyses. A multiple linear regression showed that Iba1 cell density was significantly associated with greater AT8 positive tau pathology density (B = 0.013, p = 0.001) in APOE ε4 positive, but not APOE ε4 negative, participants adjusting for age, sex, and Aβ\(_{1–42}\). Iba1 cell density was not significantly associated with Aβ\(_{1–40}\) or Aβ\(_{1–42}\) via logistic ordinal regressions controlling for age and sex. Ordinal logistic and multiple linear regression analysis of amyloid and tau pathology with CD68 did not exhibit any significant relationships (Table 3). There is a clear difference in the relationship of Iba1, but not CD68, with tau pathology depending on the presence of the APOE ε4 allele. These results show that within APOE ε4 positive, but not APOE ε4 negative participants, microglial density is associated with increased tau pathology.

**Associations between cytokines and AD pathological markers.** We hypothesized that AD-associated cytokines would display no or weak associations with AD pathology in the absence of APOE ε4, and positive associations with pathology in APOE ε4 positive participants who are more likely to develop significant AD pathology. Within APOE ε4 negative participants, ordinal logistic regression analysis showed a negative association of Aβ\(_{1–42}\) with TNF-α (OR = 0.115, p = 0.030) controlling for age and sex (Table 4). However, within APOE ε4 positive participants, an ordinal logistic regression showed a positive association of Aβ\(_{1–42}\) with IFN-γ (p = 0.014), IL-10 (p = 0.012), and IL-4 (p = 0.005) adjusting for age and sex. The association of Aβ\(_{1–42}\) with IL-4 in the presence of APOE ε4 was still significant after a Bonferroni correction for multiple comparisons. Because high levels of TNF-α are associated with less Aβ\(_{1–42}\) in APOE ε4 negative participants, TNF-α may have a protective effect on Aβ accumulation that is lost with APOE ε4. In contrast, high levels of IL-10, IL-4, and IFN-γ
were associated with increased Aβ1–42, suggesting an altered cytokine response in the presence of APOE ε4. No cytokines displayed a significant association with Aβ1–40.

To test the hypothesis that cytokine associations with tau pathology were altered by the presence of APOE ε4, we performed multiple linear regression analyses adjusting for age, sex, and Aβ1–42 (Table 5). In APOE ε4 negative participants, IL-10 (p = 0.015), IL-13 (p = 0.003), IL-4 (p = 0.021), and IL-1α (p = 0.005) were all significantly negatively associated with AT8 tau pathology (Table 5). The negative associations of AT8 tau pathology with increased IL-13 and IL-1α remained significant after a Bonferroni correction for multiple comparisons. In APOE ε4 positive participants, there were no significant associations of cytokines with AT8. The negative association of anti-inflammatory cytokines (i.e. IL-10, IL-13, IL-4) and IL-1α with tau pathology that is lost in APOE ε4 carriers suggests an altered interaction of the brain’s immune system with pathology based on APOE genotype.

### Associations between cytokines and microglia cell density

In order to test the association between microglia and those cytokines related to tau pathology (unadjusted p < 0.05: IL-10, IL-13, IL-4, and IL-1α), linear regressions were performed adjusting for age and sex (Table 6). Iba1 microglia density was negatively

| Table 1. Demographic and neuropathological characteristics of cohort. LBD: Lewy body disease; AD: Alzheimer’s disease; CTE: Chronic Traumatic Encephalopathy; FTLD: Frontotemporal Lobar Degeneration; CAA: Cerebral Amyloid Angiopathy; Pathology prevalence represent the presence of pathology not the primary diagnosis; Control cases were defined as those lacking AD, CTE, LBD, or FTLD pathology. aχ2 test for proportions between ε4 allele absent and present groups; values presented as a percentage. bIndependent sample t-test for equality of means; values presented as mean (S.E.M). #Not all cases had remote cortical microinfarct data available (N = 144). |
|---|---|---|
| | APOE ε4 negative | APOE ε4 positive | p-value |
| **Demographics** | | | |
| Sample size (n) | 119 | 35 | — |
| Age at Deaths (yrs)b | 87.9 (0.843) | 85.9 (1.63) | 0.657 |
| Sex (% male)a | 43.7% | 45.7% | 0.788 |
| Dementiaa | 46.2% | 65.7% | 0.043 |
| **Pathology**a | | | |
| AD | 28.6% | 60.0% | 0.001 |
| CTE | 0.84% | 2.86% | 0.354 |
| LBD | 27.7% | 37.1% | 0.285 |
| Neocortical LBD | 8.40% | 8.57% | 0.975 |
| FTLD | 11.8% | 11.4% | 0.957 |
| Remote Cortical Microinfarct# | 40.4% | 40.0% | 0.969 |
| Large Infarcts | 17.6% | 22.9% | 0.488 |
| Arteriosclerosis | 86.6% | 91.4% | 0.441 |
| Atherosclerosis | 75.6% | 77.1% | 0.854 |
| CAA | 75.6% | 91.4% | 0.043 |
| **IHC cellular density (cells/mm²)b** | | | |
| AT8 | 12466 (4614) | 29741 (9678) | 0.028 |
| Iba1 | 174.96 (4.04) | 181.98 (8.47) | 0.448 |
| CD68 | 166.85 (5.72) | 187.25 (12.69) | 0.162 |
| **Imunoassay (pg/mL)b** | | | |
| Aβ1–42 | 864 (74) | 1330 (180) | 0.018 |
| Aβ1–40 | 177 (53) | 653 (156) | 0.007 |

| Table 2. Levels of AD-related cytokines by APOE genotype. Measures are presented as mean concentration (S.E.M) pg/mL; *independent sample t-test for equality of means. |
|---|---|---|
| | ε4 Negative | ε4 Positive | p-value* |
| IL-10 | 0.240 (0.007) | 0.244 (0.0153) | 0.119 |
| IL-13 | 4.02 (0.116) | 3.47 (0.135) | 0.003 |
| IL-4 | 0.302 (0.0135) | 0.261 (0.0204) | 0.004 |
| TNF-α | 0.517 (0.0161) | 0.517 (0.0236) | 0.211 |
| IL-1β | 4.38 (0.734) | 4.19 (0.716) | 0.406 |
| IL-1α | 1.46 (0.0990) | 1.34 (0.104) | 0.207 |
| IFN-γ | 1.54 (0.0452) | 1.65 (0.0941) | 0.242 |
associated with IL-4 in APOE ε4 positive participants \( (p = 0.040) \) and trended towards significance in APOE ε4 negative participants \( (p = 0.060) \). In APOE ε4 positive participants there was a trend towards a negative associate with Iba1 density and IL-10 \( (p = 0.055) \). Conversely, IL-10 exhibited a significant positive association with Iba1 microglia density in APOE ε4 positive participants \( (p = 0.023) \). None of these relationships survived Bonferroni correction for multiple comparisons. IL-13 did not display any significant association to Iba1 microglia density. Overall, the level of the anti-inflammatory cytokine IL-4 was negatively associated with microglia density and the pro-inflammatory cytokine IL-1α was associated with increased microglia density in APOE ε4 positive participants.

**Relationship with dementia.** To determine whether the two significant cytokines related to tau pathology \( (i.e. \text{IL}-13 \text{ and IL}-1\alpha) \) had an effect on dementia independent of tau pathology, we performed a logistic regression adjusting for tau pathology, Aβ1–42, Iba1, microglia density, age, and sex in APOE ε4 positive and negative groups. Only tau pathology was significantly associated with dementia (Table 7). However frontostriatal tau pathology...
Table 5. Cytokine associations with tau pathology in APOE ε4 negative and positive participants. Multiple linear regressions were run adjusting for age, sex, and Aβ1-42; *p < 0.05 after Bonferroni correction for multiple comparisons. CI, confidence interval. Log transformed values were used when needed to ensure normality. Cytokine concentration in pg/mL.

Table 6. Cytokine associations with total microglial density (Iba1) in APOE ε4 negative and positive groups. Multiple linear regressions were run adjusting for age and sex. Log transformed values were used when needed to ensure normality. Cytokine concentration in pg/mL.

Table 7. Associations with dementia in APOE ε4 negative and positive participants. Binary logistic regression adjusting for age and sex; *p < 0.05 after Bonferroni correction for multiple comparisons. Cytokine concentration in pg/mL.

displayed a greater effect on dementia in APOE ε4 positive participants (OR = 12.188, p = 0.038) than in APOE ε4 negative participants (OR = 2.542, p = 0.001).

Sensitivity analyses. In order to control for possible confounds additional analyses were performed adjusting for comorbid pathways, RNA integrity number (RIN, a measure of tissue quality), and CERAD score. Effect sizes were not changed with adjustments for comorbid pathologies, including arteriolosclerosis, atherosclerosis, and neocortical Lewy bodies or with adjustment for RIN. Adjusting for CERAD score did not significantly alter the association between Iba1 microglial density and AT8 tau pathology, suggesting the relationship is independent of Aβ plaque score.

Discussion
We examined the pathological relationships between microglia, associated cytokines, and AD pathologies within the dorsolateral frontal cortex in a community-based aging cohort of 154 participants from the Framingham Heart Study. Associations between inflammatory markers and AD pathologies were significantly altered by the presence of the APOE ε4 allele. In APOE ε4 positive participants, IL-4, IL-10, and IFN-γ were associated with increased levels of Aβ1-42. In contrast, higher levels of the cytokines IL-10, IL-13, IL-4, and IL-1α were associated with decreased tau pathology only in the absence of APOE ε4. Furthermore, higher Iba1 microglial density was associated with increased tau pathology in APOE ε4 positive participants. Compared to APOE ε4 negative participants, APOE ε4 carriers appear to adopt a potentially toxic association between inflammatory markers and Aβ1-42, and lose a potentially protective association between anti-inflammatory cytokines and the development of tau pathology.

While the exact role of APOE ε4 in the pathogenesis of AD remains unclear, our findings support its role in inflammation-mediated pathology. ApoE4 has been shown to both impair clearance of Aβ and worsen...
the inflammation caused by amyloid\textsuperscript{29,30}. The presence of APOE \(\varepsilon4\) has also been associated with increased pro-inflammatory cytokines and microglial activation. A recent study using a transgenic tau mouse model found that the presence of APOE \(\varepsilon4\) increased tau, the reactivity of microglia, and the level of pro-inflammatory cytokines\textsuperscript{31}. Pro-inflammatory cytokine release from microglia led to increased astrocyte activation further increasing inflammation. Furthermore, this study found that mice with APOE \(\varepsilon4\) had increased expression of pro-inflammatory genes and down-regulation of homeostatic genes\textsuperscript{31}.

**Implications for amyloid pathology.** The role of microglia on the development of A\(\beta\) pathology is complex and varies depending on disease state and experimental paradigm. Our results support previous work in mouse models of A\(\beta\) pathology that demonstrated TNF-\(\alpha\) decreased A\(\beta_{1-42}\) burden\textsuperscript{37} and further suggests that this potential protective effect of TNF-\(\alpha\) is present only in APOE \(\varepsilon4\) negative participants. In contrast, APOE \(\varepsilon4\) positive participants appear to gain a positive association between increased levels of cytokines IFN-\(\gamma\), IL-10, and IL-4 with A\(\beta_{1-42}\) (Table 3). It is important to note that the very large odds ratio for IL-10 and IL-4 are likely due to the low level of these cytokines in the brain. The cytokines IFN-\(\gamma\), IL-10, and IL-4 have been proposed to increase amyloid deposition in mouse models of A\(\beta\) pathology, which is supported by our findings; however, they have also been associated with decreasing A\(\beta\) levels\textsuperscript{11,20,32,33}. A study using APP transgenic mice found that increased IL-10 expression was associated with increased amyloid accumulation and increased ApoE expression, particularly within insoluble amyloid plaques\textsuperscript{30}. It is proposed that in conjunction with increased IL-10, increased ApoE in these mice significantly impairs the phagocytic ability of microglia leading to the elevated amyloid accumulation. Our results agree with these findings suggesting a detrimental effect of IL-10, IL-4, and IFN-\(\gamma\) on amyloid, particularly in the presence of ApoE4. The difference between cytokine interactions with A\(\beta_{1-42}\) in APOE \(\varepsilon4\) positive and negative participants may reflect an immune state that has an altered and detrimental function in the presence of APOE \(\varepsilon4\) (Fig. 2).

**Implications for tau pathology.** Microglia have been proposed to worsen tau pathology and to be toxic to neurons\textsuperscript{24-26}. The reciprocal relationship, that tau induces microglial activation, has also been suggested based on findings in mice that expression of tau increases Iba1 microglia density and also alters the expression of genes involved in inflammation\textsuperscript{27,28}. Simultaneous linear regression modeling supports the presence of a positive feedback loop between activated microglia cell density and tau pathology in human brain tissue\textsuperscript{7}. We found a significant association between microglial density and tau pathology, suggesting a dysfunctional role of microglia in APOE \(\varepsilon4\) positive, but not APOE \(\varepsilon4\) negative, individuals.

A previous post-mortem human study examining the middle frontal cortex found that the association of Iba1 microglia density with tau pathology varied between individuals with and without dementia\textsuperscript{7}. Here we found that Iba1 microglia density was positively associated with tau pathology but displayed a negative association in those without dementia\textsuperscript{7}. Here we found that Iba1 microglia density was associated with increasing tau pathology in APOE \(\varepsilon4\) carriers (Fig. 1), suggesting that an association with dementia may be due to APOE \(\varepsilon4\) carrier status. Further studies with larger sample sizes are needed to help determine the impact of ApoE on the interaction of microglia with pathology.

Microglia may have a variety of phenotypes that represent different activation states and functions. CD68 is present within lysosomes which are increased in activated microglia with increased phagocytic activity\textsuperscript{7,39}. Surprisingly, we found CD68 cell density was not significantly related with any markers of AD pathology. That total microglia density, but not CD68 positive microglial density, is associated with worse tau pathology suggests...
alternative phenotypes of activated microglia, or potentially astrocytes, may be involved in AD. This disconnect between Iba1 and CD68 positive microglia is supported by Minett et al. who found no association between CD68 and Iba1 labelled microglia, while finding weak relationships between other microglia markers – HLA-DR, MSR-A, and CD64 – that were also associated with AD pathology. Future studies should further delineate microglia phenotypes and potential phagocytic or lysosomal impairments involved in human AD pathology.

The relationship between microglia and tau pathology has also been reported in transgenic mouse studies. A mouse line expressing tau and human APOE demonstrated that expression of APOE ε4 was associated with increased tau phosphorylation. Furthermore, microglia mediated cell damage was shown to be greater in APOE ε4 expressing mice than those expressing APOE ε3 or APOE ε2. We found that the association of microglia and associated cytokines with tau pathology is altered by the presence of APOE ε4 in human frontal cortex as well.

The detrimental effect of microglia in the presence of APOE ε4 may be due in part to the loss of potentially protective cytokine interactions and their decreased levels in APOE ε4 positive participants (Table 2). Increasing levels of IL-10, IL-13, IL-4, and IL-1α were associated with decreased tau pathology in APOE ε4 negative participants while this effect is absent in APOE ε4 carriers (Table 5). The negative association of anti-inflammatory cytokines with tau pathology in APOE ε4 negative participants agrees with basic research studies in human cell lines that demonstrate a potentially protective effect.

A variety of proinflammatory cytokines, including IL-1α, have been implicated in AD. IL-1α in its membrane bound form has been observed on activated microglia colocalized with Aβ plaques and neurons laden with tau pathology. Additionally, in cultured human astrocytes IL-1α was found to induce tau phosphorylation. Here we found that increased IL-1α was significantly associated with decreased tau pathology independent of Aβ pathology levels within APOE ε4 negative participants and that increasing IL-1α levels were associated with increased Iba1 microglia density within APOE ε4 positive, but not APOE ε4 negative participants. Thus, the interaction between IL-1α and tau pathology appears to be altered by APOE ε4.

Tau pathology is one of the major pathological drivers of dementia in aging cohorts. The cytokines IL-13 and IL-1α were significantly associated with less tau pathology in APOE ε4 negative participants and were not independently predictive of dementia. Instead, tau pathology density in the frontal cortex was significantly associated with dementia and had a much greater effect in APOE ε4 positive than negative participants. Taken together this might suggest that IL-13 and IL-1α lessen the accumulation and detrimental effect of tau pathology in APOE ε4 negative participants and that this protective effect is lost in the presence of APOE ε4 (Fig. 2).

Tau pathology is strongly associated with brain atrophy and worsening AD. Additionally, tau pathology has previously been shown to correlate with decreased brain volumes specifically within the FHS cohort. While our study focuses on the dorsolateral frontal cortex, AD pathology involves several brain regions and appears to spare others. In aging and AD, NFTs likely begin within the entorhinal cortex and extend to limbic areas and into the neocortex, while the opposite has been observed for Aβ pathology, which may begin in the neocortex and then extend to subcortical regions. Here we modeled the dorsolateral frontal cortex which is a region where Aβ and tau pathologies converge in intermediate to severe AD. The associations here likely reflect other cortical regions, including visual association areas that have been previously implicated in early AD in this cohort. In addition, cortical layers are differentially affected by pathology such that NFTs in AD tend to involve the deep cortical layers while the plaque pathology may begin more superficially. The patterns of gliosis and regional production of cytokines within different cortical layers requires further study. Further work is needed to determine the progression of pathology in different brain regions over the course of AD.

Limitations
There were several limitations to this study. Although the FHS brain donation cohort was recruited from the larger FHS community-based study, there is likely an autopsy-based selection bias. Cytokines may be rapidly metabolized and influenced by post-mortem interval. However, adjustment for RIN, a marker of tissue degradation, showed similar results. The associations between numerous cytokines and cell types and pathologies were studied based on a priori hypotheses. Nevertheless, future studies will need to confirm these results as well as determine the role of additional cytokines and cell types.

Conclusions
The associations between microglia and related cytokines with AD pathologies in human frontal cortex were altered between APOE ε4 positive and negative participants in a community aging cohort. Increased levels of IL-10, IL-13, IL-4, and IL-1α were associated with lower levels of tau pathology in APOE ε4 negative participants, suggesting a potential protective role of the immune system in absence of APOE ε4. The negative association of both anti-inflammatory and pro-inflammatory cytokines with tau pathology is absent in APOE ε4 positive individuals, who accumulate increased levels of microglia and tau pathology. Overall, APOE ε4 appears to alter the associations of microglia and inflammatory cytokines with AD pathologies. This altered immune response may partially explain the more severe Aβ and tau pathology and increased risk for AD within APOE ε4 carriers. These findings provide support for a modulatory role of APOE in immune and glial cell function in the human brain and highlight the need to stratify by APOE genotype when studying immune interactions in AD.

Data availability
All materials, data, and associated protocols will be made available.

Received: 28 August 2019; Accepted: 5 February 2020;
Published online: 19 February 2020
References

1. Bertram, L., Lill, C. M. & Tanzi, R. E. The genetics of Alzheimer disease: back to the future. Neuron 68, 270–281, https://doi.org/10.1016/j.neuron.2010.10.013 (2010).
2. Giri, M., Zhang, M. & Lu, Y. Genes associated with Alzheimer’s disease: an overview and current status. Clin. Interv. Aging 11, 665–681, https://doi.org/10.2147/CLA.S105769 (2016).
3. Corder, E. H. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Sci. 261, 921–923 (1993).
4. Verghese, P. B., Castellano, J. M. & Holtzman, D. M. Apolipoprotein E in Alzheimer’s disease and other neurological disorders. Lancet Neurol. 10, 241–252, https://doi.org/10.1016/s1474-4422(10)70325-2 (2011).
5. Overmeyer, M. et al. Reactive microglia in aging and dementia: an immunohistochemical study of postmortem human brain tissue. Acta Neuropathol. 97, 383–392 (1999).
6. Egerer, E., Kessel, S., Eitzen, U. & Graeber, M. B. Microglial Activation in Alzheimer Disease: Association with APOE Genotype. Brain Pathol. 8, 439–447, https://doi.org/10.1111/j.1750-3639.1998.tb00166.x (2006).
7. Minett, T. et al. Microglial immunophenotype in dementia with Alzheimer’s pathology. J. Neuroinflammation 13, 135, https://doi.org/10.1186/1742-2092-13-135 (2016).
8. Tao, Q. et al. Association of Chronic Low-grade Inflammation With Risk of Alzheimer Disease in APOE Carriers. JAMA Netw. Open 1, e183397, https://doi.org/10.1001/jamanetworkopen.2018.3397 (2018).
9. Rubio-Perez, J. M. & Morillas-Ruiz, J. M. A review: inflammatory process in Alzheimer’s disease, role of cytokines. ScientificWorldJournal 2012, 756357, https://doi.org/10.1100/2012/756357 (2012).
10. Szczepanik, A. I. L-4 IL-10 and IL-13 modulate Aβ peptide-induced inflammatory and neurodegenerative responses. Mol. Neurobiol. 27, 118–126, https://doi.org/10.1007/s12035-016-0927-1 (2017).
11. Block, M. L. & Hong, J. S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol. 76, 77–98, https://doi.org/10.1016/j.proneuro.2005.06.004 (2005).
12. Zheng, C., Zhou, X. W. & Wang, J. Z. The dual roles of cytokines in Alzheimer’s disease: update on interleukins, TNF-alpha, TGF-beta and IFN-gamma. Transl. Neurodegener. 5, 7, https://doi.org/10.1186/s40035-016-0054-4 (2016).
13. Sackmann, V. et al. Anti-inflammatory (M2) macrophage media reduce transmission of oligomeric amyloid beta in differentiated SH-SY5Y cells. Neurobiol. Aging 60, 173–182, https://doi.org/10.1016/j.neurobiolaging.2017.08.022 (2017).
14. Chakrabarty, P., Herring, A., Ceballos-Diaz, C., Das, P. & Golde, T. E. Hippocampal expression of murine TNFalpha results in attenuation of amyloid deposition in vivo. Mol. Neurodegener. 6, 16, https://doi.org/10.1186/s13235-016-0297-1 (2017).
15. Stein, T. D. et al. Beta-amyloid deposition in chronic traumatic encephalopathy. Acta Neuropathol. 130, 21–34, https://doi.org/10.1007/s00401-015-1435-y (2015).
16. Tiao, C. W. & Vasan, R. S. Cohort Profile: The Framingham Heart Study (FHS): overview of milestones in cardiovascular epidemiology. Int. J. Epidemiol. 44, 1880–1813, https://doi.org/10.1093/ije/dyt337 (2015).
17. Amyloid Imaging Methods: Geometric Mean Imaging (GMI) as a Tool for Imaging the Amyloid Pathology in Alzheimer’s Disease. Acta Neuropathol. 124, 112, https://doi.org/10.1007/s00401-011-0910-3 (2012).
18. Mastrogianni, M. A., Sudol, K. L., Narrow, W. C. & Bowers, W. J. Interferon-γ (IFN-γ) differentially affects Alzheimer’s disease pathologies and induces neurogenesis in triple transgenic-AD mice. Am. J. Pathol. 175, 2076–2088, https://doi.org/10.2353/ajpath.2009.090059 (2009).
19. Gilbués-Sextier, M. V. et al. IL-10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. Neurosci. 85, 354–548, https://doi.org/10.1016/j.neurosci.2011.12.068 (2015).
20. Uchihara, T. et al. ApoE-mediated microglia activation in Alzheimer’s disease: current landscape, novel data, and future perspective. J. Neurochem. 133, 465–488, https://doi.org/10.1111/jn.13072 (2015).
21. Rodriguez, G. A., Tai, L. M. & LaDue, M. J. & Rebeck, G. W. Human APOE4 increases microglia reactivity at Abeta plaques in a mouse model of Abeta deposition. J. Neuroinflammation 11, 111, https://doi.org/10.1186/s12974-2014-11-111 (2014).
22. Shi, Y. et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tautopathy. Nat. 549, 523–527, https://doi.org/10.1038/nature24016 (2017).
23. Mastrogianni, M. A., Sudol, K. L., Narrow, W. C. & Bowers, W. J. Interferon-γ (IFN-γ) differentially affects Alzheimer’s disease pathologies and induces neurogenesis in triple transgenic-AD mice. Am. J. Pathol. 175, 2076–2088, https://doi.org/10.2353/ajpath.2009.090059 (2009).
24. Khailov, A. et al. IL-10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. Neurosci. 85, 354–548, https://doi.org/10.1016/j.neurosci.2011.12.068 (2015).
25. Uchihara, T. et al. ApoE-mediated microglia reactivity and microglial cells in Alzheimer’s disease’s brain. Neurosci. Lett. 195, 5–8 (1996).
26. Maphis, N. et al. Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. Brain Res. 138, 1738–1755, https://doi.org/10.1016/s0006-8993(97)91322-3 (1999).
27. Sasaki, A. et al. Microglial activation in brain lesions with tau deposits: comparison of human tauopathies and tau transgenic mice. Transl. Neurodegener. 1, e12, https://doi.org/10.1186/1742-2092-1-12 (2012).
28. Wang, L. et al. Expression of Tau40 induces activation of cultured rat microglial cells. PLoS One 8, e76057, https://doi.org/10.1371/journal.pone.0076057 (2013).
29. Wes, P. D. et al. Tau overexpression impacts a neuroinflammation gene expression network perturbed in Alzheimer’s disease. PLoS One 9, e100650, https://doi.org/10.1371/journal.pone.010650 (2014).
30. Rabinowitz, S. S. Macrophasts, a macrophage-restricted membrane sialoglycoprotein differentially glycosylated in response to inflammatory stimuli [published erratum appears in J. Exp. Med. 1992 Jan 1;175(1):309]. J. Exp. Med. 174, 827–836, https://doi.org/10.1083/jem.174.4.827 (1991).
31. Teusser, L. et al. Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. Am. J. Pathol. 156, 951–964, https://doi.org/10.1016/S0002-4404(10)4963-2 (2000).
Reynolds, C. H., Betts, J. C., Blackstock, W. P., Nebreda, A. R. & Anderton, B. H. Phosphorylation Sites on Tau Identified by Nanoelectrospray Mass Spectrometry. J. Neurochemistry 74, 1587–1595, https://doi.org/10.1046/j.1471-4159.2000.741587.x (2002).

Lee, M., McGeer, E. & McGeer, P. L. Activated human microglia stimulate neuroblastoma cells to upregulate production of beta amyloid protein and tau: implications for Alzheimer's disease pathogenesis. Neurobiol. Aging 36, 42–52, https://doi.org/10.1016/j.neurobiolaging.2014.07.024 (2015).

Sheng, J. G., Mrak, R. E. & Griffin, W. S. T. Enlarged and phagocytic, but not primed, interleukin-1α-immunoreactive microglia increase with age in normal human brain. Acta Neuropathologica 95, 229–234, https://doi.org/10.1007/s004010050792 (1998).

Griffin, W. S. & et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl Acad. Sci. USA 86, 7611–7615 (1989).

Tanji, K. et al. Interleukin-1 induces tau phosphorylation and morphological changes in cultured human astrocytes. Neureport 14, 413–417, https://doi.org/10.1097/01.wnr.0000059783.23521.7c (2003).

Armstrong, R. A. A critical analysis of the ‘amyloid cascade hypothesis’. Folia Neuropathologica 3, 211–225, https://doi.org/10.5114/ fn.2014.45562 (2014).

Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T. & Hyman, B. T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neur. 42, 631–631, https://doi.org/10.1221/wnl.42.3.631 (1992).

Arriagada, P. V., Marzluff, K. & Hyman, B. T. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer’s disease. Neur. 42, 1681–1681, https://doi.org/10.1221/wnl.42.9.1681 (1992).

Double, K. L. et al. Topography of brain atrophy during normal aging and Alzheimer’s disease. Neurobiol. Aging 17, 513–521, https://doi.org/10.1016/s0197-4580(96)00005-x (1996).

Rascher, S. L. et al. Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline. Neuro. 89, 2176–2186, https://doi.org/10.1221/WNL.0000000000046670 (2017).

Cavedo, E. et al. Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. Neuro. 94, e30–e41, https://doi.org/10.1221/WNL.0000000000086906 (2020).

Kaur, B. et al. Association between neuropathology and brain volume in the Framingham Heart Study. Alzheimer Dis. Assoc. Disord. 28, 219–225, https://doi.org/10.1016/0022-510x(89)90197-4 (1989).

Braak, H., Braak, E., Bohl, J. & Lang, W. Alzheimer’s disease: amyloid plaques in the cerebellum. J. Neurological Sci. 93, 277–287, https://doi.org/10.1016/0022-510x(89)90197-4 (1989).

Braak, H., Thal, D. R., Ghebremedhin, E. & Del Tredici, K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 70, 960–969, https://doi.org/10.1016/j.jnen.2011.06.013 (2011).

McKee, A. C. et al. Visual association pathology in preclinical Alzheimer disease. J. Neuropathol. Exp. Neurol. 65, 621–630, https://doi.org/10.1093/jenepen/pvn003 (2016).

Acknowledgements
This study received support from the National Institute on Aging (P30AG13846 and supplement 0572063345, RF1AG054156, R56AG057768, R01AG057768, R01AG016495, R01AG033040), US Department of Veterans Affairs (I01CX001038), Alzheimer’s Association (NIRG-305779, AARF-17-529888). The views, opinions and/or findings contained in this article are those of the authors and should not be construed as an official Veterans Affairs position, policy or decision, unless so designated by other official documentation.

Author contributions
Study design and conception: J.F, N.A. and T.S. Acquisition, analysis, and/or interpretation of data: J.F, N.A., J.C., O.S., W.X., R.N., S.S., G.M., G.J., H.R., R.A. and T.S. Drafting and revising of the manuscript: All authors contributed to drafting and/or critically revising the manuscript. All authors have given final approval of the version to be published and agree to be accountable for the work.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to T.D.S.

Reprints and permissions information
is available at www.nature.com/reprints.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020